CellOPTIQ® offers significant advantages over other platforms
A broad range of reference and therapeutic compounds have been tested to demonstrate that CellOPTIQ®:
Is predictive of the clinical setting (correlates well with patient ECG)
Is predictive of in vivo models especially compounds with multi ion channel effects or effects on contractility
Offers significant advantages over other platforms
Provides very low false negative liability
Pharma Case Studies
Validation Experiments with Pharmaceutical Companies’ Compounds Demonstrate the Power of CellOPTIQ®
Modalities Comparison
Comparison of CellOPTIQ with Rabbit Wedge and Other Modalities Using 19 Reference Compounds
CellOPTIQ® outclasses many of the comparable platforms, especially in the identification of known reference compounds. CellOPTIQ® was the only platform without a false negative liability.
CellOPTIQ® Generates Data Which is Predictive of the Clinical Setting
Positive correlation observed between results of Axiogenesis hiPSC-CMs tested in vitro on CellOPTIQ® system and human EP treated with same range of Quinidine concentrations.
